Language: BG BG
nav.cta
← Back to results
Active (not recruiting) Phase 2 2023-505945-19-00

Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE

Phase 2 – studying effectiveness and dosage
Conditions: stage II melanoma

Sponsor: Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

trial.available_in: БГ
Overview
Trial status: Authorised
Who can participate
Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 90 participants
Locations 3
Germany (1)
Netherlands (1)
Sweden (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
05.02.2024
Registry ID
2023-505945-19-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.